Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Waters Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Udit Batra

İcra Kurulu Başkanı

US$8.7m

Toplam tazminat

CEO maaş yüzdesi	12.6%
CEO görev süresi	4.1yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	3.4yrs
Yönetim Kurulu ortalama görev süresi	3.5yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Udit Batra'un ücretlendirmesi Waters'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 29 2024	n/a	n/a	US$596m
Mar 30 2024	n/a	n/a	US$604m
Dec 31 2023	US$9m	US$1m	US$642m
Sep 30 2023	n/a	n/a	US$653m
Jul 01 2023	n/a	n/a	US$675m
Apr 01 2023	n/a	n/a	US$689m
Dec 31 2022	US$9m	US$1m	US$708m
Oct 01 2022	n/a	n/a	US$697m
Jul 02 2022	n/a	n/a	US$702m
Apr 02 2022	n/a	n/a	US$705m
Dec 31 2021	US$9m	US$1m	US$693m
Oct 02 2021	n/a	n/a	US$695m
Jul 03 2021	n/a	n/a	US$660m
Apr 03 2021	n/a	n/a	US$616m
Dec 31 2020	US$6m	US$285k	US$522m

Tazminat ve Piyasa: Udit 'nin toplam tazminatı ($USD 8.74M ), UK pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 5.83M ).

Tazminat ve Kazançlar: Udit 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Udit Batra (53 yo)

4.1yrs

Görev süresi

US$8,742,180

Tazminat

Dr. Udit Batra, PhD, has been the President, Chief Executive Officer and Director at Waters Corporation since September 1, 2020. Dr. Batra served as Chief Executive Officer of Life Science business of Merc...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Udit Batra	President	4.1yrs	US$8.74m	Veri yok
Amol Chaubal	Senior VP & CFO	3.4yrs	US$2.66m	0.0022% $ 455.1k
Jianqing Bennett	Senior Vice President of TA Instruments Division & Waters Clinical Business Unit	3.4yrs	US$2.11m	0.0047% $ 966.0k
Christos Ross	Senior Vice President of Global Operations	2.3yrs	Veri yok	Veri yok
Caspar Tudor	Director of Investor Relations	no data	Veri yok	Veri yok
Keeley Aleman	Senior VP	5yrs	US$2.05m	0.0034% $ 695.0k
Kristen Garvey	Vice President of Corporate Communications	5.8yrs	Veri yok	Veri yok
Patrick Conway	Interim Vice President of Human Resources	less than a year	Veri yok	Veri yok
Daniel Rush	Senior Vice President of Strategy & Transformation	3.8yrs	Veri yok	Veri yok
Robert Carpio	Senior Vice President of Waters Division	less than a year	Veri yok	0.0038% $ 783.9k
John Lynch	Treasurer	no data	Veri yok	Veri yok

3.4yrs

Ortalama Görev Süresi

50yo

Ortalama Yaş

Deneyimli Yönetim: 0LTI 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.4 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Udit Batra	President	4.1yrs	US$8.74m	Veri yok
Linda Baddour	Independent Director	6.1yrs	US$334.86k	0% $ 0
Christopher Kuebler	Independent Director	18.4yrs	US$328.86k	0.025% $ 5.1m
Richard Fearon	Independent Director	1.6yrs	US$256.04k	0.0028% $ 575.0k
Mark Vergnano	Independent Director	1.9yrs	US$312.36k	0.0082% $ 1.7m
Daniel Brennan	Independent Director	1.9yrs	US$321.36k	0.0028% $ 585.4k
Pearl Huang	Independent Director	3.8yrs	US$322.36k	0.0043% $ 887.4k
Flemming Ornskov	Independent Chairman	7.3yrs	US$480.36k	0% $ 0
Wei Jiang	Independent Director	3.3yrs	US$307.86k	0.0033% $ 682.6k
Heather Knight	Director	less than a year	Veri yok	0.00028% $ 57.9k

3.5yrs

Ortalama Görev Süresi

66yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 0LTI 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.5 yıldır).

Waters Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Waters Corporation, Annual General Meeting, May 23, 2024

Waters Corporation Announces Resignation of Jonathan Pratt as Senior Vice President of the Waters Division

Independent Director recently bought US$998k worth of stock

Waters Corporation Announces Executive Changes

Independent Director recently sold US$354k worth of stock

High number of new directors

Recent updates

Waters Corporation Announces New Bioseparations Tools Accelerate and Improve Development of Rna-Based Vaccines and Therapies Using LC-MS Analysis

Waters Corporation Introduces TA Instruments Discovery Core Rheometer

Now 21% undervalued

Second quarter 2024 earnings released: EPS: US$2.41 (vs US$2.56 in 2Q 2023)

Waters Corporation to Report Q2, 2024 Results on Jul 31, 2024

Waters Corporation New Rapid Screening-DSC Enables Up to 24x Faster Thermal Stability Testing at Ultra-Low Sample Volumes for Antibody Drugs

Now 21% undervalued after recent price drop

Waters Corporation Provides Earnings Guidance for the Second Quarter and Full Year of 2024

First quarter 2024 earnings released: EPS: US$1.73 (vs US$2.39 in 1Q 2023)

Waters Corporation Accelerates the Development of Gene-Based Therapeutics with New GTxResolve Premier SEC Columns

Waters Corporation, Annual General Meeting, May 23, 2024

Full year 2023 earnings released: EPS: US$10.87 (vs US$11.80 in FY 2022)

Full year 2023 earnings released: EPS: US$10.87 (vs US$11.80 in FY 2022)

Waters Corporation Provides Earnings Guidance for the First Quarter and Full-Year 2024

Third quarter 2023 earnings released: EPS: US$2.28 (vs US$2.61 in 3Q 2022)

Waters Corporation Announces Resignation of Jonathan Pratt as Senior Vice President of the Waters Division

Now 20% undervalued after recent price drop

Waters Corporation Launched OligoWorks SPE Workflow and Kits

Waters Corporation Introduces DynaPro™? ZetaStar™? Instrument from its Wyatt Technology™? Portfolio for Nanoparticle Analysis

Waters Corporation Provides Earnings Guidance for the Third Quarter and Full Year 2023

Second quarter 2023 earnings released: EPS: US$2.56 (vs US$2.74 in 2Q 2022)

Waters Corporation Launches XBridge Premier GTx BEH SEC Columns for Gene Therapy Applications

Waters Corporation Boosts Resolution and Triples Scan Speed of Select Series MRT for Metabolomics and MS Imaging

Waters Corporation Provides Earnings Guidance for the Second Quarter of 2023 and Fiscal Year 2023

First quarter 2023 earnings released: EPS: US$2.39 (vs US$2.64 in 1Q 2022)

Independent Director recently bought US$998k worth of stock

Waters Corporation Provides Earnings Guidance for the First Quarter of 2023 and Fiscal Year 2023

Full year 2022 earnings released: EPS: US$11.80 (vs US$11.25 in FY 2021)

Waters Corporation Announces Waters_Connect™ System Monitoring

Waters Corporation Announces Executive Changes

Independent Director recently sold US$354k worth of stock

High number of new directors

Waters Corporation Appoints Dan Brennan and Mark Vergnano to Board of Directors

Waters Introduces New PFAS Quantitation Workflow Enabled by Enhancements to Waters_Connect Informatics Platform

Third quarter 2022 earnings released: EPS: US$2.61 (vs US$2.63 in 3Q 2021)

Waters Corporation Provides Earnings Guidance for the Fourth Quarter and Full Year of 2022

Waters Automates Solid Phase Extraction of Biological, Food and Environmental Samples with Andrew+ Pipetting Robot

Waters Extends Capabilities of Flagship Ta Instruments Rheometer for Efficient and Repeatable Powder Analysis

Now 22% undervalued after recent price drop

Second quarter 2022 earnings released: EPS: US$2.74 (vs US$2.71 in 2Q 2021)

Waters Corporation Provides Earnings Guidance for the Third Quarter Ending October 1, 2022 and Full Year Ending December 31, 2022

Waters Corporation to Report Q2, 2022 Results on Aug 02, 2022

Waters Corporation(NYSE:WAT) dropped from Russell 1000 Value-Defensive Index

Waters Corporation Introduces High Resolution Mass Spectrometry Products and Software to Accelerate Drug Development

Waters Corporation Provides Earnings Guidance for the Quarter Ending July 2, 2022 and Full Year Ending December 31, 2022

First quarter 2022 earnings released: EPS: US$2.64 (vs US$2.38 in 1Q 2021)

Waters Corporation, Annual General Meeting, May 24, 2022

Waters Corporation Announces Resignation of John Ballbach from the Board of Directors

Waters Introduces Xevo TQ Absolute

Now 21% undervalued after recent price drop

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Waters Corporation Provides Earnings Guidance for the First Quarter Ending April 2, 2022 and Year Ending December 31, 2022

Third quarter 2021 earnings released: EPS US$2.63 (vs US$2.05 in 3Q 2020)

High number of new directors

High number of new directors

Independent Director Michael Berendt has left the company

Waters Corporation Introduces the Waters™ BioAccord™ System

Lead Independent Director recently sold US$3.4m worth of stock

Waters Corporation Provides Earnings Guidance for the Third Quarter and Full Year 2021

Second quarter 2021 earnings released: EPS US$2.71 (vs US$1.99 in 2Q 2020)

Waters Corporation Introduces TRIOS AutoPilot Software

Waters Corp. Introduces the Waters Arc Premier System

Waters Corporation Introduces the Sars-Cov-2 Lc-Ms Kit (Ruo) to Advance Clinical Research of Infectious Diseases

Independent Director recently sold US$369k worth of stock

Independent Director has left the company

First quarter 2021 earnings released: EPS US$2.38 (vs US$0.86 in 1Q 2020)

Waters Corporation Provides Earnings Guidance for the Three Months Ended July 3, 2021 and for the Full Year Ended December 31, 2021

Waters Corporation Introduces A New Peptide Multi-Attribute Method Workflow for the Waters BioAccord LC-MS System

Waters Corporation Improves Ease and Reliability of Small Molecule Analysis with ACQUITY RDa Detector